期刊文献+

盐酸埃克替尼对肺癌细胞增殖和凋亡的影响 被引量:14

Effects of icotinib hydrochloride on the proliferation and apoptosis of human lung cancer cell lines
原文传递
导出
摘要 目的探讨盐酸埃克替尼对不同肺癌细胞系细胞增殖和凋亡的影响。方法运用0~40μmol/L浓度的盐酸埃克替尼和吉非替尼分别处理体外培养的人肺癌细胞系HCC827、H1650、H1975、A549及人表皮癌细胞系A431,应用四甲基偶氮唑蓝比色法观察细胞增殖活力的改变,用流式细胞仪检测药物对细胞凋亡的影响,同时应用免疫印迹法观察下游信号通路的改变。结果盐酸埃克替尼作用于A431和HCC827细胞系的半数抑制浓度分别为(0.04±0.02)、(0.15±0.06)txmol/L。盐酸埃克替尼与吉非替尼相比,对A431、HCC827、H1650、H1975和A549细胞系的抑制作用差异均无统计学意义(均P〉0.05)。与H1650、H1975和A549细胞系相比,盐酸埃克替尼可显著抑制A431和HCC827细胞系的生长(P值分别为0.009、0.005、0.000和0.001、0.001、0.000)。盐酸埃克替尼可以通过抑制人表皮生长因子受体(EGFR)磷酸化活性使磷酸化的蛋白激酶B(AKT)、胞外信号调节激酶(ERK)和凋亡抑制基因survivin蛋白表达下调。结论盐酸埃克替尼可通过抑制AKT.ERK通路以及survivin通路的激活,特异性控制EGFR突变或EGFR过表达的肺癌细胞系的增殖并促进其凋亡。 Objective To explore the effects of icotinib on the proliferation and apoptosis of various lung cancer cell lines. Methods Human lung cancer cell lines HCC827, H1650, H1975, A549 and human epidermal cancer cell line A431 were treated in vitro with icotinib or gefitinib at a concentration gradient of 0 -40 μmol/L. Their proliferation effects were analyzed by the thiazoiyl blue (MTY) assay and the apoptotic effects detected by flow cytometer. The downstream signaling proteins were detected by Western blot. Results The median inhibitory concentrations (ICso) of icotinib for A431 and HCC827 cell lines were (0. 04 ± 0. 02) and (0. 15 ± 0. 06) μmol/L respectively. No significant differences existed between the inhibitions of gefitinib and icotinib on A431, HCC827, H1650, H1975 and A549 cell lines ( all P 〉 0. 05). Compared with H1650, H1975 and A549 cell lines, icotinib significantly inhibited A431 ( P = 0. 009, 0. 005 and 0. 000) and HCC827 (P -0. 001, 0. 001 and 0. 000) cell lines. And it lowered the expressions of p-AKT, p-ERK and survivin protein expression through the inhibited activity of p-EGFR protein. Conclusion Icotinib can arrest the proliferation of lung adenocarcinoma cells with EGFR mutation or overexpression by inhibiting the signal pathways of AKT-ERK and survivin.
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第36期2561-2564,共4页 National Medical Journal of China
基金 国家高新技术研究发展计划(863计划)生物和医药技术领域体外诊断技术产品开发重大项目(2011AA02A110) 国家科技重大专项(2008ZX09312)
关键词 盐酸埃克替尼 肺肿瘤 受体 表皮生长因子 细胞增殖 细胞凋亡 Icotinibhydrochloride Lung neoplasms Receptor, epidermal growth factor Cellproliferation Apoptosis
  • 相关文献

参考文献3

二级参考文献62

  • 1刘峰,姜斌,龚圣济,姚宝娣,张文颖,朱冠山,朱忠政,龚玉芳,王美玲,胡晓华.中国人非小细胞肺癌EGFR和K-RAS基因突变情况的研究[J].中华医学遗传学杂志,2007,24(1):31-34. 被引量:13
  • 2Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med,2002,346:92-98.
  • 3Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma.N Engl J Med,2009,361:948-957.
  • 4Sharma SV,Bell DW,Settleman J,et al.Epidermal growth factor receptor mutations in lung cancer.Nat Rev Cancer,2007,7:169-181.
  • 5Jackman D,Pao W,Riely GJ,et al.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.J Clin Oncol,2010,28:357-360.
  • 6Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst,2000,92:205-216.
  • 7National Cancer Institute.Common Terminology Criteria for Adverse Events V3.0 (CTCAE)[DB/OL].[2006-08-09].http://ctep.cancer.gov/protocol Development/electronic_applications/docs/ctcaev 3.polf.
  • 8Kuo CH,Lin SM,Lee KY,et al.Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.Clin LungCancer,2010,11:51-56.
  • 9Shepherd FA,Dancey J,Ramlau R,et al.Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy.J Clin Oncol,2000,18:2095-2103.
  • 10Di Maio M,Chiodini P,Georgoulias V,et al.Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.J Clin Oncol,2009,27:1836-1843.

共引文献25

同被引文献106

  • 1关忠民,陈笑艳,钟大放,王印祥.LC/MS/MS法测定比格犬血浆中埃克替尼及其在药动学研究中的应用[J].中国临床药理学与治疗学,2008,13(10):1158-1162. 被引量:2
  • 2Schiller JH, Harrington D, Belani CP, et al. Comparison of fourchemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med,2002,346: 92-98.
  • 3Scagliotti GV, Parikh P, van Pawel J, et al. Phase IH study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Onco1,2008,26: 3543-3551.
  • 4Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase II[ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004,22 : 1589-1597.
  • 5Ciuleanu T, Brodowiez T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet,2009,374 : 1432-1440.
  • 6Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase ~I, randomized, open- label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol,2011,29: 2866-2874.
  • 7Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer ( EURTAC ) : a multicentre, open-label, randomised phase 3 trial. Lancet Oncol,2012,13 : 239-246.
  • 8Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation- positive non-small-cell lung cancer ( OPTIMAL, CTONG-0802) : a muhicentre,open-label,randomised, phase 3 study. Lancet Oncol, 2011,12: 735-742.
  • 9Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005,353 : 123-132.
  • 10Shi Y,Zhang L,Liu X,et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Onco1,2013,14 : 953-961.

引证文献14

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部